סינגיס - Synagis
ש××× ×× !
×ת×ר××: 22/05/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 22/05/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | J06BD Antiviral monoclonal antibodies | |||||
|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | ת××-שר××¨× - I.M | |||||
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Abbosynagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: ⢠Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.⢠Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.⢠Children less than 2 years of age and with haemodynamically significant congenital heart disease. | |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ס×× ××ס ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ABBVIE S.R.L., ITALY |
| ×©× ××¢× ×ר×ש×× | ASTRAZENECA (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 7/2015. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 22/05/2025 |
ת××× ×ª ×ר×××